Cannabidiol

• Eleven abstracts emphasize Jazz's leadership in neuroscience and commitment to advance understanding of sleep disorders, epilepsy and movement disorders
  DUBLIN, April 19, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eleven abstracts from across its neuroscience portfolio and pipeline, including three oral presentations, will be featured at the 75th Annual American Academy of Neurology Meeting (AAN) being held April 22-27, 2023 in Boston.
• "Jazz has long been at the forefront of providing novel therapies and support for patients living with serious neurologic conditions.
• Highlights at the 2023 AAN Annual Meeting include:
  Three posters demonstrating the impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates), the first and only low-sodium oxybate, on narcolepsy patients.
• Two oral presentations of retrospective analyses of U.S. healthcare claims that estimate the prevalence of diagnosed and drug-treated essential tremor (ET) in adult and pediatric patients.

• In people with advanced cancer, psychedelic drugs like psilocybin, LSD and MDMA may significantly reduce the severity of depression and anxiety symptoms.
• However, current research suggests that available prescription antidepressants do not significantly decrease depressive symptoms in cancer patients compared with a placebo.
• My team and I recently completed a meta-analysis of five clinical trials examining anxiety and depression symptoms in patients with advanced forms of cancer and other life-threatening diseases.

Psychedelics and trauma

• People who develop PTSD from military service or physical or sexual violence commonly experience depression and anxiety.
• Based on this research, my team and I hypothesize that psychedelic sessions might have an advantage over traditional prescription antidepressants for patients with cancer-related depression or anxiety because it may help them deal with their underlying trauma.
• Patients stated that the psychedelic sessions helped them process the intense feelings they were repressing without being overwhelmed.

Unknowns in psychedelic therapy

• A number of the advanced cancer studies we examined included people with a history of psychedelic use.
• People with prior positive recreational psychedelic experiences may be more likely to participate in these studies than those who experienced a “bad trip” or were opposed to recreational drugs altogether.
• Additionally, even though the placebo was made to look identical, it is unlikely that patients or caregivers were fooled if it did not elicit a psychedelic effect.

Next steps for psychedelics

• More research is needed on effectiveness of psychedelics to treat anxiety and depression in cancer patients.
• Exploring psychedelic treatments for patients with other life-threatening diseases that cause trauma, anxiety or depression could clarify their potential therapeutic benefits.
• Were the Food and Drug Administration to approve psychedelics for this kind of use, the agency would need to figure out how these psychedelics can be used legally.

• The Doctors Brand has now become an officially trademarked brand, meaning that the natural products offered at MDbio Wellness are supported by the latest in modern medical science (including plant-based medicines) and can continue to be unique in the industry for their innovation, quality, potency, and safety.
• “We are thrilled that the revolutionary products that MDbio has worked so hard on putting out are backed by our trademarked brand.
• We know these products have the potential to help so many lives out there,” said Babak Larian, MD, FACS & Founder.
• To find out more about MDbio Wellness, The Doctor’s Brand, and their full-spectrum hemp and plant-based wellness products, please visit the website at mdbiowellness.com .

• Greeley, Colorado, April 04, 2023 (GLOBE NEWSWIRE) -- Vantage Hemp Co. (“Vantage” or the “Company”) announces that it has submitted a Drug Master File (DMF) for its cannabidiol (CBD) Isolate to the U.S. Food & Drug Administration (FDA).
• The Company establishes itself as a transparent and reliable partner to both clients and regulatory bodies through this engagement.
• "Drug Master Files move the CBD industry forward with professionalism and legitimacy," says Deepank Utkhede, Vantage’s Chief Operating Officer.
• Vantage’s submission of CBD Isolate reinforces its dedication to meeting the highest standards of quality and safety in all aspects of its business.